Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
- Market Cap ₹ 8.00 Cr.
- Current Price ₹ 2.00
- High / Low ₹ 2.94 / 1.90
- Stock P/E
- Book Value ₹ 1.12
- Dividend Yield 0.00 %
- ROCE -3.76 %
- ROE -16.0 %
- Face Value ₹ 1.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -20.8% over past five years.
- Promoter holding is low: 20.0%
- Company has a low return on equity of 1.46% over last 3 years.
- Company has high debtors of 927 days.
- Promoter holding has decreased over last 3 years: -27.8%
- Working capital days have increased from 132 days to 277 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 3 | 6 | 2 | 9 | 9 | 9 | 14 | 14 | 3 | 107 | |
| 0 | 0 | 0 | 4 | 6 | 2 | 10 | 9 | 9 | 13 | 14 | 3 | 107 | |
| Operating Profit | -0 | -0 | -0 | -0 | 1 | -0 | -0 | 0 | 0 | 1 | 1 | -0 | -0 |
| OPM % | -5% | 10% | -1% | -3% | 1% | 1% | 5% | 6% | -12% | -0% | |||
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 0 | -1 | -0 |
| Tax % | 0% | 0% | 0% | 0% | 11% | 0% | 0% | 33% | 0% | 17% | 26% | 0% | |
| -0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 0 | -1 | -0 | |
| EPS in Rs | -0.01 | -0.01 | -0.32 | -0.04 | 0.06 | -0.11 | -0.05 | 0.02 | 0.12 | 0.14 | 0.08 | -0.18 | -0.08 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -21% |
| 3 Years: | -32% |
| TTM: | 2004% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -230% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -32% |
| 3 Years: | -50% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 4% |
| 3 Years: | 1% |
| Last Year: | -16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 0.19 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | -4 | -4 | -0 | -0 | -0 | -1 | -1 | -1 | -0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 4 | 7 | 3 | 6 | 7 | |
| 0 | 0 | 0 | 3 | 5 | 6 | 9 | 4 | 6 | 9 | 9 | 4 | 33 | |
| Total Liabilities | 1 | 1 | 1 | 7 | 10 | 11 | 12 | 8 | 14 | 20 | 17 | 14 | 45 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 1 | 1 | 1 | 5 | 8 | 9 | 10 | 6 | 12 | 19 | 15 | 12 | 43 | |
| Total Assets | 1 | 1 | 1 | 7 | 10 | 11 | 12 | 8 | 14 | 20 | 17 | 14 | 45 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | -2 | -0 | 1 | 3 | -3 | -1 | 0 | 2 | -2 | |
| 0 | 0 | 0 | 2 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | |
| 0 | 0 | 0 | -2 | -1 | -1 | -3 | 3 | 1 | -0 | -2 | 2 | |
| Net Cash Flow | 0 | 0 | -0 | -2 | -1 | -0 | 0 | -0 | -0 | 0 | -0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 267 | 287 | 911 | 250 | 242 | 294 | 313 | 263 | 927 | |||
| Inventory Days | 215 | 150 | 352 | 34 | 17 | 96 | 45 | 51 | 255 | |||
| Days Payable | 304 | 319 | 1,060 | 325 | 164 | 236 | 244 | 231 | 447 | |||
| Cash Conversion Cycle | 178 | 118 | 203 | -41 | 95 | 154 | 114 | 82 | 735 | |||
| Working Capital Days | 369 | 251 | 656 | 139 | 156 | 52 | 46 | 73 | 277 | |||
| ROCE % | -8% | -8% | -10% | -5% | 14% | -1% | 6% | 18% | 15% | 12% | 9% | -4% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees absolute |
|
||||||||||
| Trade Receivables Turnover Ratio (Standalone) times |
|||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Copy of newspaper advertisment published in English daily newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region, where the …
-
Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI (LODR) Regulations, 2015.
12 Feb - Confirms no public/rights/preferential issue proceeds; Reg 32 deviation statement not applicable.
- Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025 12 Feb
-
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025
12 Feb - Board approved standalone and consolidated unaudited results for quarter and nine months ended 31-Dec-2025 with limited review.
-
Board Meeting Intimation for Consideration Of Financial Result For The Quarter And Nine Months Ended 31St December, 2025
5 Feb - Board meeting on Feb 12, 2026 to approve unaudited Q3/9M results; trading window closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products